Grifols minority shareholders team up to ask for a board seat
MADRID, Sept 20 (Reuters) -Three investment funds with holdings in Spanish drugmaker Grifols GRLS.MC have teamed up to ask to fill a vacant seat on the company's board, they said in a statement late on Thursday.
Flat Footed LLC, along with Mason Capital Management LLC and Sachem Head Capital Management LP, which hold a combined 7.72% stake in Grifols, picked Paul Herendeen, a former senior executive at other large pharmaceutical companies, to be their representative on the company's board, the statement said.
They said Grifols, which produces plasma-based medicines, had "an attractive growth profile" and its shares were undervalued and they wanted to make sure any takeover offer would include "a price that is fair for all shareholders".
Grifols lost a third of its market value in January when short-seller fund Gotham City Research started releasing several reports accusing Grifols of overstating earnings and understating debt. Following the reports Grifols announced governance changes and revised its reported leverage higher.
The Grifols family, which holds a stake of around 30% in the company, and Canadian fund Brookfield BN.TO agreed in July to evaluate a possible joint takeover bid for Grifols shares with the intent to delist it.
Grifols earlier this month said the founding family and Brookfield were in the process of due diligence and had not made any decision on an offer yet.
Reporting by Natalia Siniawski; Editing by Emelia Sithole-Matarise
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
